Analyst Reco. Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
43.08 ^USD	-1.69%		-5.40%	+16.56%

May. 22	Halozyme Therapeutics Insider Sold Shares Worth $905,480, According to a Recent SEC Filing	MT
May. 07	Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Halozyme Therapeutics Insider Sold Shares Worth $905,480, According to a Recent SEC Filing	May. 22	MT
Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing	Apr. 18	MT
HC Wainwright Adjusts Halozyme Therapeutics Price Target to $50 From $48, Maintains Buy Rating	Feb. 21	MT
Goldman Sachs Cuts Halozyme Therapeutics' Price Target to $40 From $45, Keeps Neutral Rating	Jan. 18	MT
HC Wainwright Cuts Halozyme Therapeutics Price Target to $48 From $61, Maintains Buy Rating	Jan. 18	MT
Morgan Stanley Cuts Halozyme Therapeutics Price Target to $59 From $61, Maintains Overweight Rating	Dec. 26	MT
HC Wainwright Adjusts Price Target on Halozyme Therapeutics to $61 From $60, Keeps Buy Rating	23-10-19	MT
Morgan Stanley Adjusts Price Target on Halozyme Therapeutics to $61 From $60, Keeps Overweight Rating	23-08-10	MT
Goldman Sachs Downgrades Halozyme Therapeutics to Neutral From Buy, Raises Price Target to $45 From $43	23-07-24	MT
HC Wainwright Starts Halozyme Therapeutics at Buy With $61 Price Target	23-07-24	MT
Morgan Stanley Adjusts Price Target on Halozyme Therapeutics to $60 From $64, Maintains Overweight Rating	23-05-10	MT
Piper Sandler Upgrades Halozyme Therapeutics to Overweight From Neutral With $46 Price Target	23-05-10	MT
Berenberg Bank Resumes Coverage on Halozyme Therapeutics With Buy Rating, $58 Price Target	23-03-27	MT
Wells Fargo Adjusts Price Target on Halozyme Therapeutics to $48 From $55, Maintains Overweight Rating	23-03-17	MT
Wells Fargo Adjusts Halozyme Therapeutics' Price Target to $55 From $65, Keeps Overweight Rating	23-03-16	MT
SVB Securities Downgrades Halozyme Therapeutics to Market Perform From Outperform, Price Target is $42	23-03-16	MT
Morgan Stanley Adjusts Halozyme Therapeutics Price Target to $64 From $65, Maintains Overweight Rating	23-03-06	MT
JPMorgan Adjusts Price Target on Halozyme Therapeutics to $52 From $54, Maintains Overweight Rating	23-02-23	MT
JMP Securities Adjusts Price Target on Halozyme Therapeutics to $66 From $62, Maintains Market Outperform Rating	23-02-22	MT
Morgan Stanley Assumes Halozyme Therapeutics at Overweight Rating, Adjusts Price Target to $65 From $53	22-12-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Analyst Reco.

Filters